HUP0300770A2 - Tiazolidindion-származék tartarátsója - Google Patents

Tiazolidindion-származék tartarátsója Download PDF

Info

Publication number: HUP0300770A2
Authority: HU; Hungary
Prior art keywords: meso; tartrate; solvate; substantially identical; pyridyl
Prior art date: 2000-08-04

Application number

HU0300770A

Other languages

English (en)

Hungarian (hu)

Inventor

Andrew Simon Craig

Tim Chien Ting Ho

Michael Millan

Original Assignee

Smithkline Beecham P.L.C.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-04

Filing date

2001-08-03

Publication date

2003-11-28

2001-08-03 Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.

2003-11-28 Publication of HUP0300770A2 publication Critical patent/HUP0300770A2/hu

Links

150000003892 tartrate salts Chemical class 0.000 title description 4
150000001467 thiazolidinediones Chemical class 0.000 title 1
FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims abstract description 61
239000012453 solvate Substances 0.000 claims abstract description 30
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims abstract description 9
238000004519 manufacturing process Methods 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 28
206010012601 diabetes mellitus Diseases 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 18
239000004480 active ingredient Substances 0.000 claims description 11
238000000034 method Methods 0.000 claims description 11
238000000634 powder X-ray diffraction Methods 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 11
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 7
238000001228 spectrum Methods 0.000 claims description 6
238000001237 Raman spectrum Methods 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
238000001035 drying Methods 0.000 claims description 5
239000012943 hotmelt Substances 0.000 claims description 5
238000002329 infrared spectrum Methods 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
239000007790 solid phase Substances 0.000 claims description 5
230000001954 sterilising effect Effects 0.000 claims description 5
238000004659 sterilization and disinfection Methods 0.000 claims description 5
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
238000012545 processing Methods 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 3
238000010128 melt processing Methods 0.000 claims description 3
238000003801 milling Methods 0.000 claims description 3
239000007909 solid dosage form Substances 0.000 claims description 3
238000001694 spray drying Methods 0.000 claims description 3
239000007921 spray Substances 0.000 claims description 2
239000008186 active pharmaceutical agent Substances 0.000 abstract 4
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
239000000203 mixture Substances 0.000 description 24
239000000047 product Substances 0.000 description 16
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000007787 solid Substances 0.000 description 10
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 9
238000002844 melting Methods 0.000 description 9
239000000243 solution Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
-1 5-[4-{2-[N-methyl-N-(2-pyridyl)amino]ethoxy}benzyl]-2,4-dioxothiazolidine meso-tartrate salt Chemical class 0.000 description 8
230000008018 melting Effects 0.000 description 8
239000002904 solvent Substances 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
239000000126 substance Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010022489 Insulin Resistance Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
150000001340 alkali metals Chemical class 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
UUDLQDCYDSATCH-NUGIMEKKSA-N (2r,3s)-2,3-dihydroxybutanedioic acid;hydrate Chemical compound O.OC(=O)[C@@H](O)[C@@H](O)C(O)=O UUDLQDCYDSATCH-NUGIMEKKSA-N 0.000 description 2
208000000103 Anorexia Nervosa Diseases 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
239000013543 active substance Substances 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000000113 differential scanning calorimetry Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
230000007704 transition Effects 0.000 description 2
238000009827 uniform distribution Methods 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical class O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
238000005079 FT-Raman Methods 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
201000002451 Overnutrition Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical group CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
238000012769 bulk production Methods 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000002131 composite material Substances 0.000 description 1
208000012696 congenital leptin deficiency Diseases 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
238000005388 cross polarization Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
239000011521 glass Substances 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
238000000449 magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
208000001022 morbid obesity Diseases 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000006286 nutrient intake Nutrition 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000020823 overnutrition Nutrition 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
235000020374 simple syrup Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002076 thermal analysis method Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
235000000112 undernutrition Nutrition 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
229910052726 zirconium Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Cosmetics (AREA)

HU0300770A 2000-08-04 2001-08-03 Tiazolidindion-származék tartarátsója HUP0300770A2 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0019226.0A GB0019226D0 (en)	2000-08-04	2000-08-04	Novel pharmaceutical
PCT/GB2001/003514 WO2002012233A1 (fr)	2000-08-04	2001-08-03	Sels de tartrate de derive de thiazolidinedione

Publications (1)

Publication Number	Publication Date
HUP0300770A2 true HUP0300770A2 (hu)	2003-11-28

Family

ID=9897028

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0300770A HUP0300770A2 (hu)	2000-08-04	2001-08-03	Tiazolidindion-származék tartarátsója

Country Status (23)

Country	Link
EP (1)	EP1307448A1 (fr)
JP (1)	JP2004505971A (fr)
KR (1)	KR20030022356A (fr)
CN (1)	CN1458930A (fr)
AP (1)	AP2003002737A0 (fr)
AU (1)	AU2001276508A1 (fr)
BG (1)	BG107605A (fr)
BR (1)	BR0112984A (fr)
CA (1)	CA2417828A1 (fr)
CZ (1)	CZ2003314A3 (fr)
EA (1)	EA200300231A1 (fr)
EC (1)	ECSP034468A (fr)
GB (1)	GB0019226D0 (fr)
HU (1)	HUP0300770A2 (fr)
IL (1)	IL154277A0 (fr)
MA (1)	MA25830A1 (fr)
MX (1)	MXPA03001086A (fr)
NO (1)	NO20030508L (fr)
OA (1)	OA12355A (fr)
PL (1)	PL360702A1 (fr)
SK (1)	SK1452003A3 (fr)
WO (1)	WO2002012233A1 (fr)
ZA (1)	ZA200300962B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE39384E1 (en)	1993-09-01	2006-11-07	Smithkline Beecham P.L.C.	Substituted thiazolidinedione derivatives
FR2845602B1 (fr) *	2002-10-11	2005-07-08	Servier Lab	Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
US7264813B2 (en)	2003-09-24	2007-09-04	Nikken Sohonsha Corporation	Therapeutic uses of Dunaliella powder
CN102532122B (zh) *	2010-12-29	2015-12-02	开封制药(集团)有限公司	酒石酸罗格列酮的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds

2000
- 2000-08-04 GB GBGB0019226.0A patent/GB0019226D0/en not_active Ceased
2001
- 2001-08-03 OA OA1200300029A patent/OA12355A/en unknown
- 2001-08-03 IL IL15427701A patent/IL154277A0/xx unknown
- 2001-08-03 KR KR10-2003-7001605A patent/KR20030022356A/ko not_active Withdrawn
- 2001-08-03 WO PCT/GB2001/003514 patent/WO2002012233A1/fr not_active Ceased
- 2001-08-03 AP APAP/P/2003/002737A patent/AP2003002737A0/en unknown
- 2001-08-03 CA CA002417828A patent/CA2417828A1/fr not_active Abandoned
- 2001-08-03 CZ CZ2003314A patent/CZ2003314A3/cs unknown
- 2001-08-03 CN CN01815682A patent/CN1458930A/zh active Pending
- 2001-08-03 PL PL01360702A patent/PL360702A1/xx not_active Application Discontinuation
- 2001-08-03 EA EA200300231A patent/EA200300231A1/ru unknown
- 2001-08-03 HU HU0300770A patent/HUP0300770A2/hu unknown
- 2001-08-03 EP EP01954161A patent/EP1307448A1/fr not_active Withdrawn
- 2001-08-03 JP JP2002518208A patent/JP2004505971A/ja active Pending
- 2001-08-03 MX MXPA03001086A patent/MXPA03001086A/es unknown
- 2001-08-03 SK SK145-2003A patent/SK1452003A3/sk unknown
- 2001-08-03 AU AU2001276508A patent/AU2001276508A1/en not_active Abandoned
- 2001-08-03 BR BR0112984-8A patent/BR0112984A/pt not_active IP Right Cessation
2003
- 2003-01-31 NO NO20030508A patent/NO20030508L/no not_active Application Discontinuation
- 2003-02-03 MA MA27022A patent/MA25830A1/fr unknown
- 2003-02-04 EC EC2003004468A patent/ECSP034468A/es unknown
- 2003-02-04 ZA ZA200300962A patent/ZA200300962B/en unknown
- 2003-02-28 BG BG107605A patent/BG107605A/bg unknown

Also Published As

Publication number	Publication date
ECSP034468A (es)	2003-03-31
NO20030508D0 (no)	2003-01-31
IL154277A0 (en)	2003-09-17
NO20030508L (no)	2003-03-20
BG107605A (bg)	2003-09-30
MXPA03001086A (es)	2003-05-27
CN1458930A (zh)	2003-11-26
EP1307448A1 (fr)	2003-05-07
WO2002012233A1 (fr)	2002-02-14
GB0019226D0 (en)	2000-09-27
EA200300231A1 (ru)	2003-06-26
KR20030022356A (ko)	2003-03-15
JP2004505971A (ja)	2004-02-26
ZA200300962B (en)	2003-10-29
CZ2003314A3 (cs)	2004-02-18
BR0112984A (pt)	2003-06-10
OA12355A (en)	2004-03-19
CA2417828A1 (fr)	2002-02-14
MA25830A1 (fr)	2003-07-01
SK1452003A3 (en)	2004-05-04
PL360702A1 (en)	2004-09-20
AU2001276508A1 (en)	2002-02-18
AP2003002737A0 (en)	2003-03-31

Publication	Publication Date	Title
HUP0300777A2 (hu)	2003-11-28	Tiazolidindion-származék tartarátsója
KR100770513B1 (ko)	2007-10-25	5-[4-[2-(ｎ-메틸-ｎ-(2-피리딜)아미노)에톡시]벤질]티아졸리딘-2,4-디온의 하이드로클로라이드 염
HUP0300778A2 (hu)	2003-11-28	Tiazolidindion-származék tartarátsója
JP2005515987A (ja)	2005-06-02	ロジグリタゾンエディシレート抗糖尿病剤としてのその使用
HUP0301137A2 (hu)	2003-08-28	Dioxo-tiazolidin-só diabetes mellitus kezelésére, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény
KR20030022356A (ko)	2003-03-15	티아졸리딘디온 유도체의 타르타르산염
HUP0300724A2 (hu)	2003-11-28	Tiazolidindion-származék tartarátsója
KR100917953B1 (ko)	2009-09-21	5-[4-[2-(ｎ-메틸-ｎ-(2-피리딜)아미노)에톡시]벤질]티아졸리딘-2,4-디온의 나트륨염
JP2004508370A (ja)	2004-03-18	チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
HUP0301799A2 (hu)	2003-12-29	5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-hidrojodid alkalmazása diabetetes mellitus kezelésére, eljárás a vegyület előállítására és ezt tartalmazó gyógyszerkészítmény
HUP0301199A2 (hu)	2003-11-28	Dioxo-tiazolidin-származék és antidiabetikumként történő alkalmazása
US20040102485A1 (en)	2004-05-27	Tartrate salt of thiazolidinedione derivative
KR20040062963A (ko)	2004-07-09	5-(4-(2-(ｎ-메틸-ｎ-(2-피리딜)아미노)에톡시)벤질)티아졸리딘-2,4-디온 벤젠술포네이트, 그의 제조 방법, 그의다형체 ⅰ, ⅱ 및 ⅲ, 및 제약상 활성 성분으로서의 그의용도
HK1057358B (en)	2008-05-30	Tartrate salt of thiazolidinedione derivative